Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Effector Therapeutics Inc (EFTR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Locust Walk Acquisition's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.200 +0.040    +1.85%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.198
-0.002
-0.091%
22:21:00 - Real-time Data
  • Volume: 144,737
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.120 - 2.290
Type:  Equity
Market:  United States
Locust Walk Acquisition 2.200 +0.040 +1.85%

Locust Walk Acquisition Company Profile

 
Read the Effector Therapeutics Inc company profile to learn more about the business and the management team. View Locust Walk Acquisition Corp facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Contact Information

Address 142 North Cedros Avenue Suite B
Solana Beach, 92075
United States
Phone 858 925 8215
Fax -

Top Executives

Name Age Since Title
Ross L. Levine 49 - Member of Scientific Advisory Board
Barbara A. Kosacz 62 2021 Independent Director
Elizabeth P. Bhatt 53 2021 Independent Director
Christopher B. Ehrlich 51 2020 CEO & Director
Caroline M. Loewy 54 2021 Independent Director
Brian G. Atwood 68 2021 Independent Chairman of the Board
Robert L. Garnick 71 - Member of Scientific Advisory Board
Adam Knight - - Member of Scientific Advisory Board
Rachel Wallach Humphrey 60 - Member of Scientific Advisory Board
Michael Dyszel - - Member of Scientific Advisory Board
Jeremy Goldberg - - Chairman of Scientific Advisory Board
Mike Hodges - - Member of Scientific Advisory Board
Stephen T. Worland 64 2012 CEO, President & Director
Brian M. Gallagher 52 2021 Independent Chairman
Jennifer A. Doudna 59 - Member of Clinical & Scientific Advisory Board
Joan S. Brugge - - Member of Clinical & Scientific Advisory Board
Kevan M. Shokat - - Co-Founder and Member of Clinical & Scientific Advisory Board
Barbara J. Klencke 66 2021 Independent Director
Kristen Harrington-Smith 50 2022 Independent Director
Neal Rosen 73 - Member of Clinical & Scientific Advisory Board
Davide Ruggero - - Co-Founder and Member of Clinical & Scientific Advisory Board
Kapil Dhingra 64 - Member of Clinical & Scientific Advisory Board
Robert J. Schneider - - Member of Clinical & Scientific Advisory Board
Sarat Chandarlapaty - 2023 Member of Clinical & Scientific Advisory Board
Funda Meric-Bernstam - - Member of Clinical & Scientific Advisory Board
Christopher B. Ehrlich 53 2021 Independent Director
Elizabeth P. Bhatt 55 2021 Independent Director
Caroline M. Loewy 56 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EFTR Price Commentary

Write your thoughts about Locust Walk Acquisition Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Peter Bee
Peter Bee Aug 25, 2022 13:16
Saved. See Saved Items.
This comment has already been saved in your Saved Items
😈
Peter Bee
Peter Bee Aug 25, 2022 11:13
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ᵦₒᵣᵢₙg
Peter Bee
Peter Bee Aug 18, 2022 17:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🅱🅴🅻🅸🅴🆅🅴 🅽🅾🅱🅾🅳🆈
Peter Bee
Peter Bee Aug 18, 2022 17:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
believe nobody
Peter Bee
Peter Bee Aug 17, 2022 18:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
scammer
Peter Bee
Peter Bee Aug 17, 2022 18:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🅕🅤🅒🅚 🅾🅵🅵
Peter Bee
Peter Bee Aug 17, 2022 18:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🅕🅤🅒🅚🅾🅵🅵
Peter Bee
Peter Bee Aug 17, 2022 18:07
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🅕🅤🅒🅚
Peter Bee
Peter Bee Aug 17, 2022 10:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ʞɔnⅎ
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email